drugset
drugset / Trial / NCT00725348

An Open-Label, Multi-Center Trial in the Treatment of Subjects With Moderate to Severe Plaque Type Psoriasis

NCT00725348 ↗

Phase 2 Completed 19 enrolled Stiefel, a GSK Company
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a study of a new oral drug used for the treatment of psoriasis. All subjects will get active medication, there is no placebo arm.

Timeline

Start
2004-04
Primary completion
2005-03
Completion
2006-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Talarozole Small molecule 1 mg Oral

Indications

psoriasis